<DOC>
	<DOCNO>NCT01098461</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter , 4-parallel-group , dose range study evaluate dose response , efficacy safety subcutaneously inject GSK716155 ( albiglutide ) Japanese subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Dose Ranging Study Albiglutide Japanese Subjects</brief_title>
	<detailed_description>This Phase IIb , randomize , double-blind , placebo-controlled , multicenter , 4-parallel-group , dose ranging , superiority study evaluate dose response , efficacy safety weekly every week subcutaneously inject GSK716155 ( albiglutide ) subject type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subject historical diagnosis type 2 diabetes mellitus currently treat diet exercise one OAD BMI ≥18 kg/m2 &lt; 35 kg/m2 Screening HbA1c 7.0 % 10.0 % , inclusive Fasting Cpeptide ≥0.8 ng/mL ( ≥0.26 nmol/L ) Female subject childbearing potential must practice adequate contraception . Able willing monitor his/her blood glucose concentration home glucose monitor . Able willing provide write informed consent Diagnosis type 1 diabetes mellitus Uncorrected thyroid dysfunction Previous use insulin within one month prior screen , seven total day insulin treatment within three month prior screen Clinically significantly cardiovascular and/or cerebrovascular disease include , limited following : Previous history stroke transient ischemic attack Active , unstable coronary heart disease within past six month Screening Documented myocardial infarction within one year Screening Any cardiac surgery include percutaneous transluminal coronary angioplasty , coronary stent placement , coronary artery bypass graft surgery within one year Screening Unstable angina Clinically significant arrhythmia valvular heart disease Current heart failure NYHA class II IV Resting systolic pressure &gt; 160 mm Hg diastolic pressure &gt; 95 mm Hg Screening ECG criterion Screening Heart rate : &lt; 40 &gt; 110 bpm PR interval : &lt; 120 &gt; 210 msec QRS interval : &lt; 70 &gt; 120 msec QTc interval ( Bazett ) : &gt; 450 msec &gt; 480 msec bundle branch block Fasting triglyceride level &gt; 400 mg/dL Screening AST ALT &gt; 2xULN , ALP bilirubin &gt; 1.5xULN ( except know Gilbert 's syndrome fractionate bilirubin show conjugate bilirubin &lt; 35 % total bilirubin ) If female , currently lactate , within 6 week postpartum , pregnant , actively try become pregnant Has significant renal disease manifest one following : Creatinine clearance screen &lt; 60 mL/min ( calculate CockcroftGault formula ) Screening Known loss kidney either surgical ablation , injury disease level A hemoglobinopathy may affect determination HbA1c level History treat diabetic gastroparesis History significant gastrointestinal surgery , include gastric bypass banding , surgery think significantly affect upper gastrointestinal function Current ongoing symptomatic biliary disease history acute/chronic pancreatitis . Lipase amylase Screening &gt; ULN Severe diabetic neuropathy , preproliferative retinopathy proliferative retinopathy , history ketoacidosis hyperosmolar coma History cancer , squamous cell basal cell carcinoma skin , full remission least 3 year Screening . ( A history treat cervical intraepithelial neoplasia I cervical intraepithelial neoplasia II allow ) Acute chronic history liver disease , positive hepatitis B surface antigen ( HBsAg ) positive hepatitis C test Screening Current history alcohol substance abuse Clinically significant anaemia abnormal haematological profile consider investigator clinically significant Prior use GLP1 analog Known allergy formulation excipients , Baker 's yeast , history drug , allergy , opinion responsible study physician , contradict participation History family history medullary carcinoma thyroid . History family history multiple endocrine neoplasia type 2 Receipt investigational drug within 12 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>dose-ranging</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Japan</keyword>
	<keyword>albiglutide</keyword>
</DOC>